1. Right-First-Time Innovation Approach Drives Continual Investment

    Adam Kujath, Site Director at Alcami discusses implementing a right-first-time approach for optimum results.

  2. Ensuring Confidence in Viral Vector Manufacturing

    Christopher Murphy, Chief Manufacturing Officer and Michael Wourms, Associate Director of Fill Finish for Brammer Bio discuss the company’s viral vector development and manufacturing services.

  3. Designing Effective Drug Formulations: Keys to Successful Proof of Concept Services

    Ed Scholtz, Ph.D., Vice President of R&D for UPM Pharmaceuticals explains the company's approach to formulations. 

  4. Overcoming Formulation Challenges with Liquid-fill Capsules
    Eli Elias, Director of Business Development for CapsCanada discusses how liquid-filled hard-shell capsules enable formulators to overcome challenges with complex API.
  5. Biosimilars: Are We on the Edge of a New Era of Biologics?

    Experts weigh in on our Roundtable question.

  6. Innovating Equipment: Inline Buffer Dilution Technology

    Nice Insight is in conversation with Kimo Sanderson, at Asahi Kasei Bioprocess America, to discuss the company’s “technology of the decade.”

  7. New Treatment for Management of Opioid Withdrawal Symptoms Approved by FDA

    Lucemyra (lofexidine hydrochloride) from US WorldMeds LLC is the first non-opioid treatment for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids.

  8. RNA-Modifying Proteins May Provide New Drug Targets

    Startup Accent Therapeutics raises $40 million to investigate.

  9. Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine

    The clinical program aims to develop a vaccine for populations at highest risk of infection: infants through maternal immunization, and older adults through direct vaccination.

  10. Evotec and Celgene Enter into Strategic Oncology Partnership

    Under the terms of the agreement, Evotec will receive an upfront payment of $ 65 m and may be eligible to receive significant milestone payments as well as tiered royalties on each licensed program.

  11. Fully Supporting Customer Needs for Biologics Development and Manufacturing

    James Park, Senior Vice President and Global Head, Business Development Center for Samsung BioLogics discusses the construction of three state-of-the-art production facilities in the last seven years.

  12. Focused on Fermentation

    Capua BioServices continues to invest to support modern fermentation, explains Elise Mous Director Sales & Marketing/Business Development and Thomas De Maria, Business Development Manager.

  13. From Qualified to Ideal: The Importance of Partnership
    Nice Insight's virtual panelists weigh in on what makes contract service relationships work best.
  14. Nice Insight Overview: The Key to Pharma’s Next Generation Success

    Evolving markets are prompting drug owners and developers to pursue new business models in the post-blockbuster era.

  15. Supporting Parenteral Development and Manufacturing with End-to-End Services

    Oskar Gold, Senior Vice President of Key Account Management and Marketing/Corporate Communications for Vetter, explains leveraging end-to-end support.

  16. In Close Supplier-Partner Relationships, What Pitfalls Do You Try to Avoid? How Close is Too Close?

    Experts weigh in on our Roundtable question.

  17. FDA Approves New Migraine Treatment

    The first-in-class injectable, Aimovig, gains approval.

  18. New Single-Pill HIV Treatment Approved in Europe

    Juluca from ViiV Healthcare is the first 2-drug regimen offered in a once-daily pill.

  19. FDA Approves the First Non-Opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults

    Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority.

  20. LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint

    Results showed that adjunctive treatment with LYRICA 14 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo. 

Nice Insight Awareness/Perception Scorecard

Research. Compare. Contact. Find the Ideal Partner.

Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.

  1. Search by company type, region, market segment and services.
  2. Select up to 5 companies to compare.
  3. View CA & CP performance scores against industry benchmark ratings.
FDA Approval

New Treatment for Management of Opioid Withdrawal Symptoms Approved by FDA

May 24, 2018 12:33:52 PM PAO-M05-18-NI-019
Drug Discovery

RNA-Modifying Proteins May Provide New Drug Targets

May 24, 2018 12:31:12 PM PAO-M05-18-NI-018
CRO Market

Strong Growth of CRO Market Expected to Continue

May 24, 2018 10:54:12 AM PAO-M05-18-NI-017
Drug Development

Bacteria in the Stomach Found to Play a Role in Multiple Sclerosis

May 24, 2018 10:43:06 AM PAO-M05-18-NI-016

New Single-Pill HIV Treatment Approved in Europe

May 22, 2018 1:53:45 PM PAO-M05-18-NI-015
FDA Approval

FDA Approves New Migraine Treatment

May 22, 2018 1:50:08 PM PAO-M05-18-NI-014

Cancer Immunotherapies Reach Patients More Quickly Than Other Drugs

May 18, 2018 11:48:11 AM PAO-M05-18-NI-013

Researchers Develop Diagnostic for Rare Cancer-Generated Glycoproteins

May 18, 2018 11:43:59 AM PAO-M05-18-NI-012
Cell and Gene Therapy

Editas Founders Start New Gene Editing Company

May 17, 2018 12:40:28 PM PAO-M05-18-NI-011

Medigene, Bluebird Bio Collaboration on TCR Immunotherapy Extended

May 17, 2018 12:33:28 PM PAO-M05-18-NI-010
Used Equipment

With Expertise Comes Security

May 17, 2018 9:46:56 AM PA-M05-18-CL-001

Roche’s TECENTRIQ (Atezolizumab) Receives Priority Review

May 15, 2018 11:30:45 AM PAO-M05-18-NI-009

Eli Lilly Makes Two Acquisitions in the Oncology Space

May 15, 2018 11:14:39 AM PAO-M05-18-NI-008

Nice Insight Overview

M&A Activity in a Fragmented CDMO Market
While there has been a slowdown in M&A in the pharmaceutical industry, the contract services market remains highly fragmented and players large and small continue to enhance their competitiveness through inorganic growth.


M&A: What Role has M&A Played in your Company’s Growth?

In Conversation

Operational Excellence in Outsourced Fill-Finish Services
Nice Insight is in conversation with Oskar Gold at Vetter Pharma International, a global leader in the fill-finish of aseptically prefilled syringe systems, cartridges and vials, about how outsourced supply of such services can help companies of all sizes.

In Conversation

M&A: Combining Market Segments

Dago Caceres and Gary Lord, The Dow Chemical Company